Altium Capital Management L.P. 13F annual report
Altium Capital Management L.P. is an investment fund managing more than $222 billion ran by Mark Gottlieb. There are currently 45 companies in Mr. Gottlieb’s portfolio. The largest investments include Vera Therapeutics Inc and Xenon Pharmaceuticals Inc, together worth $45.6 billion.
$222 billion Assets Under Management (AUM)
As of 8th May 2024, Altium Capital Management L.P.’s top holding is 710,000 shares of Vera Therapeutics Inc currently worth over $30.6 billion and making up 13.8% of the portfolio value.
In addition, the fund holds 348,000 shares of Xenon Pharmaceuticals Inc worth $15 billion, whose value grew 39.2% in the past six months.
The third-largest holding is Axsome Therapeutics Inc worth $11 billion and the next is Adma Biologics Inc worth $10.2 billion, with 1,540,000 shares owned.
Currently, Altium Capital Management L.P.'s portfolio is worth at least $222 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Altium Capital Management L.P.
The Altium Capital Management L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Mark Gottlieb serves as the Chief Operating Officer at Altium Capital Management L.P..
Recent trades
In the most recent 13F filing, Altium Capital Management L.P. revealed that it had opened a new position in
Avadel Pharmaceuticals plc and bought 553,057 shares worth $9.34 billion.
This means they effectively own approximately 0.1% of the company.
Avadel Pharmaceuticals plc makes up
6.1%
of the fund's Health Care sector allocation and has grown its share price by 11.1% in the past year.
The investment fund also strengthened its position in Vera Therapeutics Inc by buying
95,000 additional shares.
This makes their stake in Vera Therapeutics Inc total 710,000 shares worth $30.6 billion.
On the other hand, there are companies that Altium Capital Management L.P. is getting rid of from its portfolio.
Altium Capital Management L.P. closed its position in EA Series Trust on 15th May 2024.
It sold the previously owned 92,700 shares for $9.75 billion.
Mark Gottlieb also disclosed a decreased stake in Alimera Sciences by approximately 0.1%.
This leaves the value of the investment at $9.95 billion and 2,550,000 shares.
One of the smallest hedge funds
The two most similar investment funds to Altium Capital Management L.P. are Trinity Advisors and Ogborne Capital Management. They manage $222 billion and $222 billion respectively.
Mark Gottlieb investment strategy
Altium Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 68.8% of
the total portfolio value.
The fund focuses on investments in the United States as
57.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
20% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $973 million.
The complete list of Altium Capital Management L.P. trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Vera Therapeutics Inc |
15.45%
710,000
|
$30,615,200,000 | 13.77% |
| Xenon Pharmaceuticals Inc |
19.78%
348,000
|
$14,981,400,000 | 6.74% |
| Axsome Therapeutics Inc |
No change
138,000
|
$11,012,400,000 | 4.95% |
| Adma Biologics Inc |
40.64%
1,540,000
|
$10,164,000,000 | 4.57% |
| Alimera Sciences Inc. |
4.14%
2,550,000
|
$9,945,000,000 | 4.47% |
| EA Series Trust |
Closed
92,700
|
$9,747,405,000 | |
| Avadel Pharmaceuticals plc |
Opened
553,057
|
$9,341,133,000 | 4.20% |
| Xtant Med Hldgs Inc |
4.73%
7,647,873
|
$8,948,011,000 | 4.03% |
| Catalyst Pharmaceuticals Inc |
29.87%
500,000
|
$7,970,000,000 | 3.59% |
| Intra-Cellular Therapies Inc |
59.15%
113,000
|
$7,819,600,000 | 3.52% |
| Biohaven Ltd |
Opened
140,000
|
$7,656,600,000 | 3.44% |
| Viking Therapeutics Inc |
Opened
85,000
|
$6,970,000,000 | 3.14% |
| Olema Pharmaceuticals, Inc. |
46.27%
605,000
|
$6,848,600,000 | 3.08% |
| Savara Inc |
0.15%
1,335,000
|
$6,648,300,000 | 2.99% |
| Soleno Therapeutics Inc |
45.75%
152,909
|
$6,544,505,000 | 2.94% |
| Cybin Inc |
Opened
13,953,488
|
$5,769,767,000 | 2.60% |
| Oric Pharmaceuticals, Inc. |
40.09%
405,000
|
$5,568,750,000 | 2.51% |
| Larimar Therapeutics, Inc. |
Opened
695,000
|
$5,275,050,000 | 2.37% |
| Mirum Pharmaceuticals Inc |
Opened
208,000
|
$5,224,960,000 | 2.35% |
| Neurogene Inc |
49.30%
100,000
|
$5,090,000,000 | 2.29% |
| Praxis Precision Medicines I |
Opened
78,100
|
$4,765,662,000 | 2.14% |
| Achieve Life Sciences Inc. |
Opened
835,470
|
$3,797,211,000 | 1.71% |
| Ascendis Pharma A/S |
No change
25,000
|
$3,779,250,000 | 1.70% |
| Longboard Pharmaceuticals In |
Opened
170,000
|
$3,672,000,000 | 1.65% |
| Immunovant Inc |
Closed
80,000
|
$3,370,400,000 | |
| Insmed Inc |
No change
120,000
|
$3,255,600,000 | 1.46% |
| The Realreal Inc |
Opened
800,000
|
$3,128,000,000 | 1.41% |
| Alpine Immune Sciences Inc |
1.11%
77,848
|
$3,085,895,000 | 1.39% |
| Boundless Bio Inc |
Opened
200,000
|
$2,850,000,000 | 1.28% |
| Aquestive Therapeutics Inc |
Opened
665,000
|
$2,832,900,000 | 1.27% |
| Cymabay Therapeutics Inc |
Closed
111,000
|
$2,621,820,000 | |
| Sagimet Biosciences Inc |
Closed
483,181
|
$2,531,634,000 | |
| Rhythm Pharmaceuticals Inc. |
783.13%
57,271
|
$2,481,552,000 | 1.12% |
| Crinetics Pharmaceuticals In |
Closed
65,000
|
$2,312,700,000 | |
| Milestone Pharmaceuticals In |
Opened
1,212,882
|
$2,171,059,000 | 0.98% |
| Astria Therapeutics Inc |
80.48%
142,532
|
$2,006,138,000 | 0.90% |
| Zevra Therapeutics Inc |
Opened
341,461
|
$1,980,474,000 | 0.89% |
| Envveno Medical Corporation |
Closed
344,471
|
$1,770,581,000 | |
| Amylyx Pharmaceuticals Inc |
Closed
119,526
|
$1,759,423,000 | |
| Cytokinetics Inc |
Closed
20,000
|
$1,669,800,000 | |
| Marinus Pharmaceuticals Inc |
11.58%
176,840
|
$1,598,634,000 | 0.72% |
| BioVie Inc. |
Opened
3,012,608
|
$1,592,465,000 | 0.72% |
| Tourmaline Bio Inc |
Opened
65,442
|
$1,498,622,000 | 0.67% |
| Veru Inc |
5.59%
2,111,731
|
$1,478,423,000 | 0.67% |
| Arvinas Inc |
Closed
31,210
|
$1,284,604,000 | |
| Fortress Biotech Inc |
Closed
405,122
|
$1,219,417,000 | |
| Karyopharm Therapeutics Inc |
No change
740,000
|
$1,117,400,000 | 0.50% |
| Spruce Biosciences, Inc. |
Opened
1,150,000
|
$903,785,000 | 0.41% |
| DiaMedica Therapeutics Inc. |
Closed
287,698
|
$817,062,000 | |
| Perspective Therapeutics Inc |
Opened
535,657
|
$637,432,000 | 0.29% |
| Advisorshares Tr |
Closed
80,000
|
$560,800,000 | |
| Doubledown Interactive Co Lt |
Closed
60,876
|
$447,408,000 | |
| Evoke Pharma Inc |
Opened
724,942
|
$442,215,000 | 0.20% |
| Perfect Moment Ltd |
Opened
92,208
|
$330,105,000 | 0.15% |
| Cassava Sciences Inc |
Closed
13,000
|
$292,630,000 | |
| Tonix Pharmaceuticals Hldg C |
Closed
540,025
|
$217,630,000 | |
| Mobilicom Ltd |
Opened
135,292
|
$160,997,000 | 0.07% |
| Gri Bio Inc |
Opened
187,981
|
$142,866,000 | 0.06% |
| Cyclacel Pharmaceuticals Inc |
Closed
37,982
|
$101,412,000 | |
| Azitra Inc |
Opened
493,153
|
$101,343,000 | 0.05% |
| Sadot Group Inc |
Closed
168,235
|
$67,378,000 | |
| Quoin Pharmaceuticals Ltd |
Opened
66,240
|
$62,928,000 | 0.03% |
| Novabay Pharmaceuticals Inc |
Closed
67,457
|
$13,761,000 | |
| No transactions found | |||
| Showing first 500 out of 63 holdings | |||
Hedge funds similar to Altium Capital Management L.P.
- David Kennon Inc
- Congress Park Capital
- Sara-bay
- Innealta Capital
- Beaconlight Capital
- Greenstone Partners & Co
- Wunderlich Capital Managemnt
- Trinity Advisors
- Ogborne Capital Management
- Client 1st Advisory Group
- Second Half Partners
- Alfreton Capital LL.P.
- Ewa
- Fortem Financial Group